查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1830309

血浆分馏市场（按产品类型、分馏方法、应用和最终用户划分）—2025-2032 年全球预测

Plasma Fractionation Market by Product Type, Method of Fractionation, Application, End-User - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 194 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年血浆分馏市场将成长 782.8 亿美元，复合年增长率为 9.90%。

主要市场统计数据
基准年2024年 367.7亿美元
预计2025年 402.2亿美元
预测年份：2032年 782.8亿美元
复合年增长率（%） 9.90%

血浆分馏领域处于先进生物製程与庞大临床需求的交汇点，推动着针对免疫力缺乏、凝血功能障碍和其他危及生命的疾病的关键治疗方法的发展。分离技术、分析平台和监管协调的最新进展，正在提高製造商和服务供应商的技术期望。同时，对以患者为中心的护理模式和罕见疾病治疗的日益关注，正在将商业性重点从商品化供应转向差异化给药方式，例如皮下免疫球蛋白治疗和综合患者支持计划。

在这种动态下，相关人员必须协调日益增长的临床复杂性与采购高品质血浆、保持批次间一致性以及确保稳健的低温运输物流的营运现实。策略相关人员正在优先投资自动化、一次性系统和流程分析技术，以减少差异性并加快放行时间。此外，从血液采集网路到合约分离器，整个价值链上的协作正成为一种竞争的必要条件，从而促进融合专业监管和技术专长与能力的伙伴关係关係。

随着产业的成熟，人们越来越重视可重复的品质和弹性的供应链，同时也更加重视服务成本和病患可及性。因此，企业策略也日益多元化，整合卓越的製造能力、专业的产品系列和地理覆盖，以在维持利润率完整性的同时获取临床价值。

技术突破、监管融合和治疗模式转变如何重塑准备行动和策略重点

过去几年，技术创新、监管环境的演变以及治疗需求的转变显着改变了血浆分馏的模式。在上游工程，强化的捐血者筛检通讯协定和改进的血浆采集基础设施提高了原料的品质；而在下游，离子交换层析法和超过滤等现代分离方法则提高了关键生技药品的纯度和产量。这些製程改进不仅提高了产品的一致性，还使製剂的稳定性和给药方案得到改善，从而扩大了可治疗的适应症范围。

同时，监管机构对病毒安全性、製程验证和可比性测试的要求也日益明确，促使企业更新验证策略并投资于高阶分析技术。这种监管明确性降低了新参与企业的技术门槛，但也提高了展示强大生产控制的门槛。在商业性方面，皮下免疫球蛋白和患者自主给药模式的兴起正在再形成分销和依从性考量，迫使製造商重新思考包装、剂量灵活性和患者教育计划。

最后，竞争动态正受到战略伙伴关係关係、契约製造扩张以及旨在缓解血浆供应区域不平衡的跨境产能投资浪潮的影响。这些变化正在加速从传统的以批量为中心的营运模式转向敏捷、以品质主导的平台转变，这些平台支持差异化疗法和更具弹性的供应。

2025 年美国关税对供应链弹性、筹资策略、合约架构和区域製造业的影响

2025年美国加征关税为全球血浆分馏供应链带来了重大变数，影响了采购选择、商业合约和跨国生产策略。关税相关的成本压力促使企业重新评估依赖进口的生产模式，并加速关键原料、专用试剂和成品药的本地化进程。为此，企业纷纷寻求多元化的供应商网络，并将製造和填充能力迁移或扩展到更靠近需求中心的地方，以减少贸易摩擦和物流延误带来的风险。

此后不久，契约製造製造商和服务提供者开始调整长期协议，因为客户要求协议中包含应对关税波动和额外成本转嫁可能性的条款。这些合约变更强调灵活性、更短的前置作业时间和应急计划，而采购团队则优先考虑多源采购和地理冗余。对于低温运输要求复杂或需要即时物流的产品，关税压力加剧了对前置作业时间波动和库存过时的担忧，凸显了改善需求预测和缓衝策略的必要性。

贸易政策的转变引发了策略转变，而非一次性的成本调整。投资于本地製造能力、透明的成本结构和稳健的供应商关係的公司发现自己更有能力维持业务并保障患者获得药品。相较之下，仍严重依赖单一国家供应链的公司面临更高的营运风险，必须加快缓解措施以保持供应的连续性。

细分主导的综合洞察，将产品差异化、分馏技术、临床应用和最终用户需求与策略要务联繫起来

細項分析揭示了产品类型、分馏方法、应用和最终用户之间的差异化动态，从而塑造了产业参与者的策略重点领域。在产品类型中，白蛋白、凝血因子浓缩物、免疫球蛋白和蛋白酶抑制剂各自展现出独特的发展路径。尤其是免疫球蛋白，进一步细分为静脉注射和皮下注射，给药途径的创新影响製剂配方和病患支持需求。这些产品特有的细微差别驱动着不同的研发重点、法规要求和商业化方法。

就製造技术而言，离心、冷沉淀、乙醇沉淀、离子交换层析法和超过滤等技术在资本强度、监管审查和规模经济方面各有不同。采用层析法和膜技术的公司优先考虑製程强化和分析控制，而依赖沉淀方法的企业则在探索混合製程架构，以提高产量和安全性。血液学、神经病学、肿瘤学和风湿病学等临床应用领域具有显着不同的治疗价值提案和报销动态，这些因素为打入市场策略和证据生成计划提供了资讯。

最后，涵盖学术机构、临床研究组织以及医院和诊所的最终使用者环境决定了服务水准期望、法律规范和采购行为。同时，医院和诊所优先考虑可靠的供应、便捷的给药方式以及能够确保依从性和安全给药的支援服务。透过整合这些细分视角，相关人员可以确定投资优先顺序、协调商业模式，并设计符合临床需求和监管复杂性的生产布局。

捐赠者准入、监管体系、报销模式和製造倡议的地区差异如何影响全球市场的策略重点

血浆分馏生态系的策略决策持续受到区域动态的影响，而区域动态又受到捐赠者基础可用性、法律规范、报销环境和医疗服务提供模式差异的影响。在美洲，成熟的采集网络和对免疫球蛋白和凝血因子的高临床需求支撑着强大的国内生产能力，而监管预期和付款人动态强调以结果为导向的证据和具有成本效益的治疗方案。这种结合既为差异化产品创造了机会，也为透过流程现代化优化成本结构带来了压力。

欧洲、中东和非洲拥有多元化的管理体制和医疗基础设施，这些地区在努力实现全部区域协调的同时，也采取了各国各自独特的采购惯例。该地区的一些市场优先考虑国家自给自足和强有力的药物安全检测，鼓励投资本地製造能力并加强品管。同时，在某些地区，需求受到专科治疗可近性的差异以及不断演变的、奖励临床价值的报销模式的影响。

亚太地区正在快速发展，这得益于医疗保健可及性的扩大、临床应用的提升以及国内生物製造投资的不断增长。一些政府正在积极推动生物技术能力建设，并支持官民合作关係，以扩大血浆采集和分离基础设施。总而言之，区域策略必须将全球最佳实践与本地区独特的监管、经济和临床现实相协调，以确保在不同医疗保健体系中实现可靠的可及性和永续的营运。

竞争格局分为垂直整合製造商、专业合约分馏商和推动差异化和供应可靠性的技术合作伙伴

血浆分馏领域的竞争格局以垂直整合的製造商、专业的合约分离商以及提供赋能平台的技术提供者为特征。领先的公司透过投资专有处理技术、可扩展的血浆采集运营，以及涵盖免疫球蛋白、凝血因子和利基血浆衍生蛋白的广泛治疗产品组合来实现差异化。策略差异化越来越依赖端到端能力，这些能力能够连接供体网路、赋能处理和临床支援服务，从而提高可靠性和患者疗效。

契约製造和专业加工合作伙伴发挥着至关重要的作用，他们提供灵活的产能和技术专长，帮助创新企业和学名药快速进入市场。这些合作伙伴正在扩展一次性加工、先进层析法和无菌填充能力，以适应复杂的生技药品和多样化的剂型。技术供应商和分析公司正在透过提供製程控制工具、病毒清除方法和验证框架，帮助加快监管核准并缩短上市时间。

在这种竞争格局下，成功的公司会部署一种紧密结合的策略，将有针对性的研发、策略伙伴关係关係、卓越营运专案与能力投资结合。他们还会优先考虑透明的供应链实践、风险共担的商业协议以及以患者为中心的服务，以维持与医疗服务提供者和付款人的长期合作关係。总体而言，规模、专业知识和合作伙伴关係的相互作用决定了该行业的竞争格局。

高阶主管领导阶层的可行策略重点是供应弹性、流程现代化、以病人为中心的商业化以及伙伴关係主导的创新

产业领导者应采取多管齐下的行动，以增强供应弹性，加速流程现代化，并使商业模式与不断发展的临床交付模式保持一致。首先，投资本地製造能力和多元化的供应商关係，可以减少贸易中断和关税波动带来的风险，同时提高对本地需求的应对力。其次，优先考虑製程改进，例如实施层析法、超过滤和自动化控制系统，可提高产量、减少差异性，并长期降低单位成本。这些技术投资应与支援可比较性、病毒安全性和加速批次放行的增强型分析平台结合。

第三，公司应调整其商业性模式，以支持机构采购商和以患者为中心的医疗模式，开发基于套件的服务，包括灵活的剂量、家庭管理支援和依从性计划。第四，应修订合约框架，纳入自适应供应协议、风险分担条款以及协调合作伙伴之间奖励的协作库存管理方法。第五，公司策略应整合永续性和捐赠者管理倡议，以保障长期血浆供应。

最后，鼓励企业与学术中心、专科诊所和技术提供者建立策略联盟，以加速创新，检验新的治疗适应症，并降低监管途径的风险。透过结合营运韧性、技术升级和伙伴关係主导的商业化，领导者可以在保持竞争优势的同时，保障患者获得重要治疗方法的管道。

我们透过结合初步访谈、设施评估、文献综述和情境分析的主要调查方法来检验营运和策略见解。

本执行摘要所依据的研究整合了原始研究和二手资料，旨在对血浆分馏领域进行严谨客观的分析。原始研究包括与行业高管、技术负责人、采购专家和临床相关人员进行结构化访谈，以获得关于生产限制、监管预期和最终用户需求的实用见解。此外，我们还进行了现场考察和技术评估，以检验製程能力并了解不同分离设施之间的操作差异。

二次研究包括同行评审文献、监管指南文件、技术白皮书和公开的企业资料，以三角测量技术趋势和政策变化。在适用的情况下，数据与多个独立资讯来源进行了交叉检验，以减少偏差并增强结论的证据力。分析方法包括定性主题分析、比较技术评估和基于情境的风险评估，以突显策略意义和营运效益。

在整个研究过程中，我们谨慎地确保假设的透明度，澄清我们数据的来源，并承认其局限性，特别是在新技术和政策变化造成持续不确定性的领域。调查方法经过量身定制，旨在为寻求使研发、製造和商业活动与不断发展的临床和监管现实保持一致的决策者提供可行的见解。

综合策略重点在于技术采用、供应多样化以及协调的商业性和营运回应，以确保未来的竞争力

总而言之，血浆分馏产业正处于一个策略曲折点，技术进步、监管明晰和临床模式的不断发展正在共同重塑产品的开发、生产和交付方式。层析法和膜分离技术的日益成熟，加上捐赠者筛检和分析技术的改进，正在提高产品质量，并实现更有利于患者的给药方法。同时，不断变化的贸易政策和捐赠者供应的地区差异，正促使企业投资于多元化的供应链和区域製造能力，以保障医疗服务的连续性。

价值链各相关人员的首要任务是将这些趋势转化为一种协作策略，在产能扩张与流程现代化和证据产生之间取得平衡。卓越的营运、有针对性的伙伴关係以及适应性的商业模式对于管理成本动态和确保满足临床需求至关重要。采用一种整合技术、商业性和地理因素的整体方法，将使组织能够抵御短期波动，同时获得长期临床影响和永续成长。

目录

第一章：前言

第二章调查方法

第三章执行摘要

第四章 市场概况

第五章 市场洞察

  • 重组疗法的扩展推动了传统血浆分馏体积的变化
  • 血浆分馏常规流程可提高效率并降低生产成本。
  • 免疫球蛋白治疗需求的不断增长推动了全球血浆采集基础设施的投资
  • 影响血浆分馏和最终产品跨境分销的监管协调挑战
  • 采用奈米过滤和病毒灭活技术增强血浆衍生产品的安全性
  • 生物製药公司与契约製造之间的策略伙伴关係扩大了全球血浆分馏能力
  • 由于外科手术和严重监护的增加，新兴市场将推动血浆衍生白蛋白的需求增加
  • 数位捐赠者招募平台对血浆供应稳定性和采集中心利用率的影响

第六章：2025年美国关税的累积影响

第七章：人工智慧的累积影响，2025年

第 8 章血浆分馏市场（依产品类型）

  • 白蛋白
  • 凝血因子浓缩物
  • 免疫球蛋白
    • 静脉注射免疫球蛋白
    • 皮下注射免疫球蛋白
  • 蛋白酶抑制剂

第九章血浆分馏市场（依分离方法）

  • 离心
  • 冷沉淀
  • 乙醇沉淀
  • 离子交换层析法
  • 超过滤

第 10 章血浆分馏市场（按应用）

  • 血液学
  • 神经病学
  • 肿瘤学
  • 风湿病学

第 11 章血浆分馏市场（按最终用户）

  • 学术机构
  • 临床研究实验室
  • 医院和诊所

第十二章血浆分馏市场（按地区）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十三章血浆分馏市场：依类别

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十四章血浆分馏市场（按国家）

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十五章竞争格局

  • 2024年市占率分析
  • 2024年FPNV定位矩阵
  • 竞争分析
    • 3M Company
    • ADMA Biologics, Inc.
    • Bharat Serums and Vaccines Limited
    • Bio Products Laboratory Ltd.
    • Biotest AG by Grifols, SA
    • China Biologic Products, Inc.
    • CSL Limited
    • Emergent BioSolutions Inc.
    • GC Biopharma corp.
    • HEINKEL Process Technology GmbH
    • Hemarus Therapeutics Ltd
    • Intas Pharmaceuticals Ltd.
    • Kamada Ltd.
    • Kedrion SpA
    • LFB SA
    • Merck KGaA
    • Octapharma AG
    • PlasmaGen BioSciences Pvt. Ltd.
    • Prothya Biosolutions BV
    • Shanghai Raas Blood Products Co. Ltd.
    • SK Plasma Co.,Ltd.
    • STERIS plc
    • Takeda Pharmaceutical Company Ltd.
Product Code: MRR-4312A385A58A

The Plasma Fractionation Market is projected to grow by USD 78.28 billion at a CAGR of 9.90% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 36.77 billion
Estimated Year [2025] USD 40.22 billion
Forecast Year [2032] USD 78.28 billion
CAGR (%) 9.90%

The plasma fractionation sector sits at the intersection of advanced bioprocessing and high-stakes clinical demand, driving critical therapies for immune deficiencies, coagulation disorders, and other life-threatening conditions. Recent advances in separation technologies, analytical platforms, and regulatory harmonization have elevated the technical expectations for manufacturers and service providers alike. In parallel, patient-centric care models and growing emphasis on rare disease therapeutics have shifted commercial priorities from commoditized supply toward differentiated delivery formats, such as subcutaneous immunoglobulin therapies, and integrated patient support programs.

Given these dynamics, stakeholders must reconcile increasing clinical complexity with the operational realities of sourcing high-quality plasma, maintaining batch-to-batch consistency, and ensuring robust cold-chain logistics. Strategic actors are prioritizing investments in automation, single-use systems, and process analytical technologies to reduce variability and accelerate time-to-release. Moreover, collaboration across the value chain-from blood collection networks to contract fractionators-has emerged as a competitive necessity, fostering partnerships that blend capacity with specialized regulatory and technical expertise.

As the industry matures, the emphasis on reproducible quality and resilient supply chains is matched by a growing focus on cost-to-serve and patient access. Consequently, corporate strategies are increasingly multidimensional, integrating manufacturing excellence, specialized product portfolios, and targeted geographies to capture clinical value while preserving margin integrity.

How technological breakthroughs, regulatory convergence, and shifting therapy delivery models are reshaping fractionation operations and strategic priorities

The past several years have ushered in transformative shifts across the plasma fractionation landscape, driven by technological innovation, regulatory evolution, and changing therapeutic needs. Upstream, enhanced donor screening protocols and improvements in plasma collection infrastructure have improved the quality profile of raw inputs, while downstream, modern fractionation modalities such as ion-exchange chromatography and ultrafiltration have enabled higher purity and yield for key biologics. These process improvements have not only increased product consistency but also expanded the repertoire of treatable indications by enabling formulations with improved stability and administration profiles.

Concurrently, regulatory agencies have converged on clearer expectations for viral safety, process validation, and comparability studies, prompting firms to modernize validation strategies and invest in advanced analytics. This regulatory clarity has lowered technical barriers for novel entrants but simultaneously raised the bar for demonstrating robust manufacturing controls. In the commercial sphere, the rise of subcutaneous immunoglobulin administration and patient self-administration models has reshaped distribution and adherence considerations, motivating manufacturers to rethink packaging, dosing flexibility, and patient education programs.

Finally, competitive dynamics have been influenced by a wave of strategic partnerships, contract manufacturing expansions, and cross-border capacity investments that aim to mitigate regional imbalances in plasma supply. Taken together, these changes are accelerating a shift from legacy batch-centric operations to agile, quality-driven platforms that support differentiated therapies and more resilient supply frameworks.

Implications of the 2025 United States tariff measures on supply chain resilience, sourcing strategies, contractual frameworks, and regional manufacturing

The imposition of tariffs in the United States in 2025 introduced a material variable into the global plasma fractionation supply chain, influencing sourcing choices, commercial contracts, and cross-border manufacturing strategies. Tariff-related cost pressures prompted firms to reassess import-dependent production models and to accelerate localization efforts for critical raw materials, specialized reagents, and finished formulations. In response, companies pursued diversified supplier networks and relocating or expanding manufacturing and fill-finish capabilities closer to demand centers to mitigate exposure to trade friction and logistical delays.

In the immediate aftermath, contract manufacturers and service providers saw adjustments to long-standing agreements as clients sought contractual provisions that addressed tariff volatility and potential passthrough of additional costs. These contractual shifts emphasized flexibility, shorter lead times, and contingency planning, while procurement teams prioritized multi-sourcing and regional redundancies. For products with complex cold-chain requirements or just-in-time logistics, tariff pressures amplified concerns about lead-time variability and inventory obsolescence, reinforcing the case for stronger demand forecasting and buffer strategies.

Over time, these trade policy shifts catalyzed strategic reorientation rather than one-off cost adjustments. Companies that invested in regional capacity, transparent costing mechanisms, and resilient supplier relationships found themselves better positioned to sustain operations and protect patient access. In contrast, organizations that remained heavily reliant on single-country supply chains faced elevated operational risk and needed to accelerate mitigation measures to preserve continuity of supply.

Integrated segmentation-driven insights linking product differentiation, fractionation methodologies, clinical applications, and end-user demands to strategic imperatives

Segmentation analysis reveals differentiated dynamics across product types, fractionation methods, applications, and end users that collectively shape strategic focus areas for industry participants. Within product categories, albumin, coagulation factor concentrates, immunoglobulins, and protease inhibitors show distinct development pathways; immunoglobulins, in particular, are further divided into intravenous immunoglobulin and subcutaneous immunoglobulin, with delivery route innovations influencing formulation and patient support requirements. These product-specific nuances drive divergent R&D priorities, regulatory requirements, and commercialization approaches.

Regarding production techniques, variations across centrifugation, cryoprecipitation, ethanol precipitation, ion-exchange chromatography, and ultrafiltration translate into different capital intensity, regulatory scrutiny, and scale economics. Players leveraging chromatographic and membrane-based methodologies are emphasizing process intensification and analytical control, while operations dependent on precipitation-based approaches are exploring hybrid process architectures to enhance yield and safety. In clinical application areas such as hematology, neurology, oncology, and rheumatology, therapeutic value propositions and reimbursement dynamics vary markedly, informing go-to-market strategies and evidence-generation plans.

Finally, the end-user landscape-spanning academic institutions, clinical research laboratories, and hospitals and clinics-dictates service-level expectations, regulatory oversight, and procurement behavior. Academic and clinical research settings often require flexible small-batch production and extensive documentation for investigational use, whereas hospitals and clinics prioritize reliable supply, dosing convenience, and support services that enable adherence and safe administration. Synthesizing these segmentation lenses enables stakeholders to prioritize investments, tailor commercial models, and design manufacturing footprints aligned with clinical demand and regulatory complexity.

How regional variations in donor access, regulatory systems, reimbursement models, and manufacturing initiatives are shaping strategic priorities across global markets

Regional dynamics continue to influence strategic decisions across the plasma fractionation ecosystem, driven by differences in donor base availability, regulatory frameworks, reimbursement environments, and healthcare delivery models. In the Americas, established collection networks and high clinical demand for immunoglobulins and coagulation factors have supported substantial domestic capacity, while regulatory expectations and payer dynamics emphasize outcome-focused evidence and cost-effective therapy delivery. This combination creates both opportunities for differentiated products and pressure to optimize cost structures through process modernization.

Europe, Middle East & Africa present a diverse mix of regulatory regimes and healthcare infrastructures, where pan-regional harmonization efforts coexist with country-specific procurement practices. Several markets in this region prioritize national self-sufficiency and robust pharmacovigilance, prompting investments in local production capabilities and tighter quality controls. Meanwhile, demand in certain territories is shaped by differential access to specialty therapies and evolving reimbursement models that reward clinical value.

Asia-Pacific exhibits a rapidly evolving landscape driven by expanding healthcare access, growing clinical adoption, and increasing investments in domestic biomanufacturing. Governments in several countries are actively promoting biotechnology capacity-building and supporting public-private partnerships to expand plasma collection and fractionation infrastructure. Taken together, regional strategies must reconcile global best practices with localized regulatory, economic, and clinical realities to enable reliable access and sustainable operations across diverse healthcare systems.

Competitive landscape shaped by vertically integrated manufacturers, specialized contract fractionators, and enabling technology partners driving differentiation and supply reliability

Competitive dynamics in the plasma fractionation sector are characterized by a mix of vertically integrated manufacturers, specialized contract fractionators, and technology providers offering enabling platforms. Leading organizations differentiate through investments in proprietary processing technologies, scale-efficient plasma collection operations, and breadth of therapeutic portfolios that span immunoglobulins, coagulation factors, and niche plasma-derived proteins. Strategic differentiation increasingly relies on end-to-end capabilities that link donor networks, validated processing, and clinical support services to enhance reliability and patient outcomes.

Contract manufacturing and specialized processing partners play a pivotal role by offering flexible capacity and technical know-how that enable faster entry for innovators and generics alike. These partners are expanding capabilities in single-use processing, advanced chromatography, and aseptic fill-finish to accommodate complex biologics and variant administration formats. Technology suppliers and analytics firms contribute by supplying process control tools, viral clearance methodologies, and validation frameworks that accelerate regulatory approval and reduce time-to-market.

Across the competitive landscape, successful companies deploy cohesive strategies that combine capacity investments with targeted R&D, strategic partnerships, and operational excellence programs. They also prioritize transparent supply chain practices, risk-sharing commercial agreements, and patient-centric services to sustain long-term relationships with healthcare providers and payers. Overall, the interplay of scale, specialized technology, and collaborative partnerships defines the competitive contours of the industry.

Actionable strategic priorities for executives focused on supply resilience, process modernization, patient-centric commercialization, and partnership-driven innovation

Industry leaders should pursue multifaceted actions that strengthen supply resilience, accelerate process modernization, and align commercial models with evolving clinical delivery paradigms. First, investment in regional capacity and diversified supplier relationships will reduce exposure to trade disruptions and tariff volatility while improving responsiveness to local demand. Second, prioritizing process intensification-through adoption of chromatography, ultrafiltration, and automated control systems-will improve yield, reduce variability, and lower unit cost over time. These technical investments should be paired with enhanced analytical platforms to support comparability, viral safety, and batch-release acceleration.

Third, firms must adapt commercial approaches to support both institutional purchasers and patient-centric care models, developing suite-based offerings that include flexible dosing, home administration support, and adherence programs. Fourth, contractual frameworks should be revisited to include adaptive supply agreements, risk-sharing clauses, and collaborative inventory management practices that align incentives across partners. Fifth, corporate strategies should integrate sustainability and donor stewardship initiatives to protect long-term plasma access, including donor engagement programs and transparent ethical sourcing practices.

Finally, organizations are advised to cultivate strategic alliances with academic centers, specialty clinics, and technology providers to accelerate innovation, validate new therapeutic indications, and de-risk regulatory pathways. By combining operational resilience, technological upgrade, and partnership-driven commercialization, leaders can sustain competitive advantage while safeguarding patient access to critical therapies.

Robust multi-source research methodology combining primary interviews, site assessments, literature review, and scenario analysis to validate operational and strategic insights

The research underlying this executive summary integrates primary and secondary approaches designed to ensure rigorous, objective analysis of the plasma fractionation landscape. Primary research included structured interviews with industry executives, technical leads, procurement specialists, and clinical stakeholders to capture practical insights on manufacturing constraints, regulatory expectations, and end-user requirements. These interviews were complemented by site visit observations and technology assessments to validate process capabilities and to understand operational heterogeneity across fractionation facilities.

Secondary research encompassed a review of peer-reviewed literature, regulatory guidance documents, technology white papers, and publicly available corporate disclosures to triangulate technical trends and policy changes. Wherever applicable, data were cross-validated against multiple independent sources to reduce bias and to strengthen the evidentiary basis for conclusions. Analytical methods incorporated qualitative thematic analysis, comparative technology evaluation, and scenario-based risk assessment to surface strategic implications and operational levers.

Throughout the research process, care was taken to ensure transparency of assumptions, clarity on data provenance, and acknowledgment of limitations, particularly where emerging technologies or policy shifts created areas of ongoing uncertainty. The methodology was calibrated to support actionable insights for decision-makers seeking to align R&D, manufacturing, and commercial activities with evolving clinical and regulatory realities.

Synthesis of strategic implications emphasizing technology adoption, supply diversification, and coordinated commercial and operational responses to secure future competitiveness

In conclusion, the plasma fractionation industry is at a strategic inflection point where technological advances, regulatory clarity, and evolving clinical models are converging to reshape how products are developed, manufactured, and delivered. The maturation of chromatographic and membrane-based fractionation technologies, paired with improved donor screening and analytics, is elevating product quality and enabling more patient-friendly administration options. At the same time, trade policy shifts and regional disparities in donor availability are prompting firms to invest in diversified supply chains and regional manufacturing capabilities to protect continuity of care.

For stakeholders across the value chain, the priority is to translate these trends into coordinated strategies that balance capacity expansion with process modernization and evidence generation. Operational excellence, targeted partnerships, and adaptive commercial models will be essential to manage cost dynamics and to meet clinical demand reliably. By embracing a holistic approach that integrates technical, commercial, and regional considerations, organizations can navigate near-term disruptions while positioning themselves to capture long-term clinical impact and sustainable growth.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Expansion of recombinant therapies driving shifts in traditional plasma fractionation volumes
  • 5.2. Integration of continuous flow processing to improve efficiency and reduce production costs in plasma fractionation
  • 5.3. Rising demand for immunoglobulin therapies prompting increased investments in global plasma collection infrastructure
  • 5.4. Regulatory harmonization challenges affecting cross-border plasma fractionation and final product distribution
  • 5.5. Adoption of nanofiltration and viral inactivation technologies enhancing safety profiles of plasma-derived products
  • 5.6. Strategic partnerships between biopharma and contract manufacturers to expand plasma fractionation capacity worldwide
  • 5.7. Emerging markets driving growth in plasma-derived albumin demand amid increasing surgical and critical care procedures
  • 5.8. Impact of donor recruitment digital platforms on plasma supply stability and collection center utilization rates

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Plasma Fractionation Market, by Product Type

  • 8.1. Albumin
  • 8.2. Coagulation Factor Concentrates
  • 8.3. Immunoglobulins
    • 8.3.1. Intravenous Immunoglobulin
    • 8.3.2. Subcutaneous Immunoglobulin
  • 8.4. Protease Inhibitors

9. Plasma Fractionation Market, by Method of Fractionation

  • 9.1. Centrifugation
  • 9.2. Cryoprecipitation
  • 9.3. Ethanol Precipitation
  • 9.4. Ion-Exchange Chromatography
  • 9.5. Ultrafiltration

10. Plasma Fractionation Market, by Application

  • 10.1. Hematology
  • 10.2. Neurology
  • 10.3. Oncology
  • 10.4. Rheumatology

11. Plasma Fractionation Market, by End-User

  • 11.1. Academic Institutions
  • 11.2. Clinical Research Laboratories
  • 11.3. Hospitals & Clinics

12. Plasma Fractionation Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Plasma Fractionation Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Plasma Fractionation Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2024
  • 15.2. FPNV Positioning Matrix, 2024
  • 15.3. Competitive Analysis
    • 15.3.1. 3M Company
    • 15.3.2. ADMA Biologics, Inc.
    • 15.3.3. Bharat Serums and Vaccines Limited
    • 15.3.4. Bio Products Laboratory Ltd.
    • 15.3.5. Biotest AG by Grifols, S.A.
    • 15.3.6. China Biologic Products, Inc.
    • 15.3.7. CSL Limited
    • 15.3.8. Emergent BioSolutions Inc.
    • 15.3.9. GC Biopharma corp.
    • 15.3.10. HEINKEL Process Technology GmbH
    • 15.3.11. Hemarus Therapeutics Ltd
    • 15.3.12. Intas Pharmaceuticals Ltd.
    • 15.3.13. Kamada Ltd.
    • 15.3.14. Kedrion S.p.A.
    • 15.3.15. LFB SA
    • 15.3.16. Merck KGaA
    • 15.3.17. Octapharma AG
    • 15.3.18. PlasmaGen BioSciences Pvt. Ltd.
    • 15.3.19. Prothya Biosolutions B.V.
    • 15.3.20. Shanghai Raas Blood Products Co. Ltd.
    • 15.3.21. SK Plasma Co.,Ltd.
    • 15.3.22. STERIS plc
    • 15.3.23. Takeda Pharmaceutical Company Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL PLASMA FRACTIONATION MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY METHOD OF FRACTIONATION, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY METHOD OF FRACTIONATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY END-USER, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY END-USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. AMERICAS PLASMA FRACTIONATION MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. NORTH AMERICA PLASMA FRACTIONATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. LATIN AMERICA PLASMA FRACTIONATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. EUROPE, MIDDLE EAST & AFRICA PLASMA FRACTIONATION MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. EUROPE PLASMA FRACTIONATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. MIDDLE EAST PLASMA FRACTIONATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. AFRICA PLASMA FRACTIONATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC PLASMA FRACTIONATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASEAN PLASMA FRACTIONATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GCC PLASMA FRACTIONATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. EUROPEAN UNION PLASMA FRACTIONATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. BRICS PLASMA FRACTIONATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. G7 PLASMA FRACTIONATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. NATO PLASMA FRACTIONATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. PLASMA FRACTIONATION MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 28. PLASMA FRACTIONATION MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. PLASMA FRACTIONATION MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL PLASMA FRACTIONATION MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL PLASMA FRACTIONATION MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY ALBUMIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY ALBUMIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY ALBUMIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY ALBUMIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY ALBUMIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY ALBUMIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY COAGULATION FACTOR CONCENTRATES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY COAGULATION FACTOR CONCENTRATES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY COAGULATION FACTOR CONCENTRATES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY COAGULATION FACTOR CONCENTRATES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY COAGULATION FACTOR CONCENTRATES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY COAGULATION FACTOR CONCENTRATES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY IMMUNOGLOBULINS, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY IMMUNOGLOBULINS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY IMMUNOGLOBULINS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY IMMUNOGLOBULINS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY IMMUNOGLOBULINS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY IMMUNOGLOBULINS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY IMMUNOGLOBULINS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY INTRAVENOUS IMMUNOGLOBULIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY INTRAVENOUS IMMUNOGLOBULIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY INTRAVENOUS IMMUNOGLOBULIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY INTRAVENOUS IMMUNOGLOBULIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY INTRAVENOUS IMMUNOGLOBULIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY INTRAVENOUS IMMUNOGLOBULIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY SUBCUTANEOUS IMMUNOGLOBULIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY SUBCUTANEOUS IMMUNOGLOBULIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY SUBCUTANEOUS IMMUNOGLOBULIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY SUBCUTANEOUS IMMUNOGLOBULIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY SUBCUTANEOUS IMMUNOGLOBULIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY SUBCUTANEOUS IMMUNOGLOBULIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY PROTEASE INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY PROTEASE INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY PROTEASE INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY PROTEASE INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY PROTEASE INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY PROTEASE INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY METHOD OF FRACTIONATION, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY METHOD OF FRACTIONATION, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY CENTRIFUGATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY CENTRIFUGATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY CENTRIFUGATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY CENTRIFUGATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY CENTRIFUGATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY CENTRIFUGATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY CRYOPRECIPITATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY CRYOPRECIPITATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY CRYOPRECIPITATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY CRYOPRECIPITATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY CRYOPRECIPITATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY CRYOPRECIPITATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY ETHANOL PRECIPITATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY ETHANOL PRECIPITATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY ETHANOL PRECIPITATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY ETHANOL PRECIPITATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY ETHANOL PRECIPITATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY ETHANOL PRECIPITATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY ION-EXCHANGE CHROMATOGRAPHY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY ION-EXCHANGE CHROMATOGRAPHY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY ION-EXCHANGE CHROMATOGRAPHY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY ION-EXCHANGE CHROMATOGRAPHY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY ION-EXCHANGE CHROMATOGRAPHY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY ION-EXCHANGE CHROMATOGRAPHY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY ULTRAFILTRATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY ULTRAFILTRATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY ULTRAFILTRATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY ULTRAFILTRATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY ULTRAFILTRATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY ULTRAFILTRATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY HEMATOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY HEMATOLOGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY HEMATOLOGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY HEMATOLOGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY HEMATOLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY HEMATOLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY NEUROLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY NEUROLOGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY NEUROLOGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY NEUROLOGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY NEUROLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY NEUROLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY ONCOLOGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY ONCOLOGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY RHEUMATOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY RHEUMATOLOGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY RHEUMATOLOGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY RHEUMATOLOGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY RHEUMATOLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY RHEUMATOLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY ACADEMIC INSTITUTIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY ACADEMIC INSTITUTIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY ACADEMIC INSTITUTIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY ACADEMIC INSTITUTIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY ACADEMIC INSTITUTIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY ACADEMIC INSTITUTIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY CLINICAL RESEARCH LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY CLINICAL RESEARCH LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY CLINICAL RESEARCH LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY CLINICAL RESEARCH LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY CLINICAL RESEARCH LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY CLINICAL RESEARCH LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY HOSPITALS & CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY HOSPITALS & CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY HOSPITALS & CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY HOSPITALS & CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 125. AMERICAS PLASMA FRACTIONATION MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 126. AMERICAS PLASMA FRACTIONATION MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 127. AMERICAS PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 128. AMERICAS PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 129. AMERICAS PLASMA FRACTIONATION MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2024 (USD MILLION)
  • TABLE 130. AMERICAS PLASMA FRACTIONATION MARKET SIZE, BY IMMUNOGLOBULINS, 2025-2032 (USD MILLION)
  • TABLE 131. AMERICAS PLASMA FRACTIONATION MARKET SIZE, BY METHOD OF FRACTIONATION, 2018-2024 (USD MILLION)
  • TABLE 132. AMERICAS PLASMA FRACTIONATION MARKET SIZE, BY METHOD OF FRACTIONATION, 2025-2032 (USD MILLION)
  • TABLE 133. AMERICAS PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 134. AMERICAS PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 135. AMERICAS PLASMA FRACTIONATION MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 136. AMERICAS PLASMA FRACTIONATION MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 137. NORTH AMERICA PLASMA FRACTIONATION MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 138. NORTH AMERICA PLASMA FRACTIONATION MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 139. NORTH AMERICA PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 140. NORTH AMERICA PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 141. NORTH AMERICA PLASMA FRACTIONATION MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2024 (USD MILLION)
  • TABLE 142. NORTH AMERICA PLASMA FRACTIONATION MARKET SIZE, BY IMMUNOGLOBULINS, 2025-2032 (USD MILLION)
  • TABLE 143. NORTH AMERICA PLASMA FRACTIONATION MARKET SIZE, BY METHOD OF FRACTIONATION, 2018-2024 (USD MILLION)
  • TABLE 144. NORTH AMERICA PLASMA FRACTIONATION MARKET SIZE, BY METHOD OF FRACTIONATION, 2025-2032 (USD MILLION)
  • TABLE 145. NORTH AMERICA PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 146. NORTH AMERICA PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 147. NORTH AMERICA PLASMA FRACTIONATION MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 148. NORTH AMERICA PLASMA FRACTIONATION MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 149. LATIN AMERICA PLASMA FRACTIONATION MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 150. LATIN AMERICA PLASMA FRACTIONATION MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 151. LATIN AMERICA PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 152. LATIN AMERICA PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 153. LATIN AMERICA PLASMA FRACTIONATION MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2024 (USD MILLION)
  • TABLE 154. LATIN AMERICA PLASMA FRACTIONATION MARKET SIZE, BY IMMUNOGLOBULINS, 2025-2032 (USD MILLION)
  • TABLE 155. LATIN AMERICA PLASMA FRACTIONATION MARKET SIZE, BY METHOD OF FRACTIONATION, 2018-2024 (USD MILLION)
  • TABLE 156. LATIN AMERICA PLASMA FRACTIONATION MARKET SIZE, BY METHOD OF FRACTIONATION, 2025-2032 (USD MILLION)
  • TABLE 157. LATIN AMERICA PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 158. LATIN AMERICA PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 159. LATIN AMERICA PLASMA FRACTIONATION MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 160. LATIN AMERICA PLASMA FRACTIONATION MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 161. EUROPE, MIDDLE EAST & AFRICA PLASMA FRACTIONATION MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 162. EUROPE, MIDDLE EAST & AFRICA PLASMA FRACTIONATION MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 163. EUROPE, MIDDLE EAST & AFRICA PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 164. EUROPE, MIDDLE EAST & AFRICA PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 165. EUROPE, MIDDLE EAST & AFRICA PLASMA FRACTIONATION MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2024 (USD MILLION)
  • TABLE 166. EUROPE, MIDDLE EAST & AFRICA PLASMA FRACTIONATION MARKET SIZE, BY IMMUNOGLOBULINS, 2025-2032 (USD MILLION)
  • TABLE 167. EUROPE, MIDDLE EAST & AFRICA PLASMA FRACTIONATION MARKET SIZE, BY METHOD OF FRACTIONATION, 2018-2024 (USD MILLION)
  • TABLE 168. EUROPE, MIDDLE EAST & AFRICA PLASMA FRACTIONATION MARKET SIZE, BY METHOD OF FRACTIONATION, 2025-2032 (USD MILLION)
  • TABLE 169. EUROPE, MIDDLE EAST & AFRICA PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 170. EUROPE, MIDDLE EAST & AFRICA PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 171. EUROPE, MIDDLE EAST & AFRICA PLASMA FRACTIONATION MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 172. EUROPE, MIDDLE EAST & AFRICA PLASMA FRACTIONATION MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 173. EUROPE PLASMA FRACTIONATION MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 174. EUROPE PLASMA FRACTIONATION MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 175. EUROPE PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 176. EUROPE PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 177. EUROPE PLASMA FRACTIONATION MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2024 (USD MILLION)
  • TABLE 178. EUROPE PLASMA FRACTIONATION MARKET SIZE, BY IMMUNOGLOBULINS, 2025-2032 (USD MILLION)
  • TABLE 179. EUROPE PLASMA FRACTIONATION MARKET SIZE, BY METHOD OF FRACTIONATION, 2018-2024 (USD MILLION)
  • TABLE 180. EUROPE PLASMA FRACTIONATION MARKET SIZE, BY METHOD OF FRACTIONATION, 2025-2032 (USD MILLION)
  • TABLE 181. EUROPE PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 182. EUROPE PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 183. EUROPE PLASMA FRACTIONATION MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 184. EUROPE PLASMA FRACTIONATION MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 185. MIDDLE EAST PLASMA FRACTIONATION MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 186. MIDDLE EAST PLASMA FRACTIONATION MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 187. MIDDLE EAST PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 188. MIDDLE EAST PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 189. MIDDLE EAST PLASMA FRACTIONATION MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2024 (USD MILLION)
  • TABLE 190. MIDDLE EAST PLASMA FRACTIONATION MARKET SIZE, BY IMMUNOGLOBULINS, 2025-2032 (USD MILLION)
  • TABLE 191. MIDDLE EAST PLASMA FRACTIONATION MARKET SIZE, BY METHOD OF FRACTIONATION, 2018-2024 (USD MILLION)
  • TABLE 192. MIDDLE EAST PLASMA FRACTIONATION MARKET SIZE, BY METHOD OF FRACTIONATION, 2025-2032 (USD MILLION)
  • TABLE 193. MIDDLE EAST PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 194. MIDDLE EAST PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 195. MIDDLE EAST PLASMA FRACTIONATION MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 196. MIDDLE EAST PLASMA FRACTIONATION MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 197. AFRICA PLASMA FRACTIONATION MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 198. AFRICA PLASMA FRACTIONATION MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 199. AFRICA PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 200. AFRICA PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 201. AFRICA PLASMA FRACTIONATION MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2024 (USD MILLION)
  • TABLE 202. AFRICA PLASMA FRACTIONATION MARKET SIZE, BY IMMUNOGLOBULINS, 2025-2032 (USD MILLION)
  • TABLE 203. AFRICA PLASMA FRACTIONATION MARKET SIZE, BY METHOD OF FRACTIONATION, 2018-2024 (USD MILLION)
  • TABLE 204. AFRICA PLASMA FRACTIONATION MARKET SIZE, BY METHOD OF FRACTIONATION, 2025-2032 (USD MILLION)
  • TABLE 205. AFRICA PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 206. AFRICA PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 207. AFRICA PLASMA FRACTIONATION MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 208. AFRICA PLASMA FRACTIONATION MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 209. ASIA-PACIFIC PLASMA FRACTIONATION MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 210. ASIA-PACIFIC PLASMA FRACTIONATION MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 211. ASIA-PACIFIC PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 212. ASIA-PACIFIC PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 213. ASIA-PACIFIC PLASMA FRACTIONATION MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2024 (USD MILLION)
  • TABLE 214. ASIA-PACIFIC PLASMA FRACTIONATION MARKET SIZE, BY IMMUNOGLOBULINS, 2025-2032 (USD MILLION)
  • TABLE 215. ASIA-PACIFIC PLASMA FRACTIONATION MARKET SIZE, BY METHOD OF FRACTIONATION, 2018-2024 (USD MILLION)
  • TABLE 216. ASIA-PACIFIC PLASMA FRACTIONATION MARKET SIZE, BY METHOD OF FRACTIONATION, 2025-2032 (USD MILLION)
  • TABLE 217. ASIA-PACIFIC PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 218. ASIA-PACIFIC PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 219. ASIA-PACIFIC PLASMA FRACTIONATION MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 220. ASIA-PACIFIC PLASMA FRACTIONATION MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 223. ASEAN PLASMA FRACTIONATION MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 224. ASEAN PLASMA FRACTIONATION MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 225. ASEAN PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 226. ASEAN PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 227. ASEAN PLASMA FRACTIONATION MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2024 (USD MILLION)
  • TABLE 228. ASEAN PLASMA FRACTIONATION MARKET SIZE, BY IMMUNOGLOBULINS, 2025-2032 (USD MILLION)
  • TABLE 229. ASEAN PLASMA FRACTIONATION MARKET SIZE, BY METHOD OF FRACTIONATION, 2018-2024 (USD MILLION)
  • TABLE 230. ASEAN PLASMA FRACTIONATION MARKET SIZE, BY METHOD OF FRACTIONATION, 2025-2032 (USD MILLION)
  • TABLE 231. ASEAN PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 232. ASEAN PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 233. ASEAN PLASMA FRACTIONATION MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 234. ASEAN PLASMA FRACTIONATION MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 235. GCC PLASMA FRACTIONATION MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 236. GCC PLASMA FRACTIONATION MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 237. GCC PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 238. GCC PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 239. GCC PLASMA FRACTIONATION MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2024 (USD MILLION)
  • TABLE 240. GCC PLASMA FRACTIONATION MARKET SIZE, BY IMMUNOGLOBULINS, 2025-2032 (USD MILLION)
  • TABLE 241. GCC PLASMA FRACTIONATION MARKET SIZE, BY METHOD OF FRACTIONATION, 2018-2024 (USD MILLION)
  • TABLE 242. GCC PLASMA FRACTIONATION MARKET SIZE, BY METHOD OF FRACTIONATION, 2025-2032 (USD MILLION)
  • TABLE 243. GCC PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 244. GCC PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 245. GCC PLASMA FRACTIONATION MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 246. GCC PLASMA FRACTIONATION MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 247. EUROPEAN UNION PLASMA FRACTIONATION MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 248. EUROPEAN UNION PLASMA FRACTIONATION MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 249. EUROPEAN UNION PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 250. EUROPEAN UNION PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 251. EUROPEAN UNION PLASMA FRACTIONATION MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2024 (USD MILLION)
  • TABLE 252. EUROPEAN UNION PLASMA FRACTIONATION MARKET SIZE, BY IMMUNOGLOBULINS, 2025-2032 (USD MILLION)
  • TABLE 253. EUROPEAN UNION PLASMA FRACTIONATION MARKET SIZE, BY METHOD OF FRACTIONATION, 2018-2024 (USD MILLION)
  • TABLE 254. EUROPEAN UNION PLASMA FRACTIONATION MARKET SIZE, BY METHOD OF FRACTIONATION, 2025-2032 (USD MILLION)
  • TABLE 255. EUROPEAN UNION PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 256. EUROPEAN UNION PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 257. EUROPEAN UNION PLASMA FRACTIONATION MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 258. EUROPEAN UNION PLASMA FRACTIONATION MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 259. BRICS PLASMA FRACTIONATION MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 260. BRICS PLASMA FRACTIONATION MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 261. BRICS PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 262. BRICS PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 263. BRICS PLASMA FRACTIONATION MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2024 (USD MILLION)
  • TABLE 264. BRICS PLASMA FRACTIONATION MARKET SIZE, BY IMMUNOGLOBULINS, 2025-2032 (USD MILLION)
  • TABLE 265. BRICS PLASMA FRACTIONATION MARKET SIZE, BY METHOD OF FRACTIONATION, 2018-2024 (USD MILLION)
  • TABLE 266. BRICS PLASMA FRACTIONATION MARKET SIZE, BY METHOD OF FRACTIONATION, 2025-2032 (USD MILLION)
  • TABLE 267. BRICS PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 268. BRICS PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 269. BRICS PLASMA FRACTIONATION MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 270. BRICS PLASMA FRACTIONATION MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 271. G7 PLASMA FRACTIONATION MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 272. G7 PLASMA FRACTIONATION MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 273. G7 PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 274. G7 PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 275. G7 PLASMA FRACTIONATION MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2024 (USD MILLION)
  • TABLE 276. G7 PLASMA FRACTIONATION MARKET SIZE, BY IMMUNOGLOBULINS, 2025-2032 (USD MILLION)
  • TABLE 277. G7 PLASMA FRACTIONATION MARKET SIZE, BY METHOD OF FRACTIONATION, 2018-2024 (USD MILLION)
  • TABLE 278. G7 PLASMA FRACTIONATION MARKET SIZE, BY METHOD OF FRACTIONATION, 2025-2032 (USD MILLION)
  • TABLE 279. G7 PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 280. G7 PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 281. G7 PLASMA FRACTIONATION MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 282. G7 PLASMA FRACTIONATION MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 283. NATO PLASMA FRACTIONATION MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 284. NATO PLASMA FRACTIONATION MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 285. NATO PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 286. NATO PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 287. NATO PLASMA FRACTIONATION MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2024 (USD MILLION)
  • TABLE 288. NATO PLASMA FRACTIONATION MARKET SIZE, BY IMMUNOGLOBULINS, 2025-2032 (USD MILLION)
  • TABLE 289. NATO PLASMA FRACTIONATION MARKET SIZE, BY METHOD OF FRACTIONATION, 2018-2024 (USD MILLION)
  • TABLE 290. NATO PLASMA FRACTIONATION MARKET SIZE, BY METHOD OF FRACTIONATION, 2025-2032 (USD MILLION)
  • TABLE 291. NATO PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 292. NATO PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 293. NATO PLASMA FRACTIONATION MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 294. NATO PLASMA FRACTIONATION MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 295. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 296. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 297. UNITED STATES PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 298. UNITED STATES PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 299. UNITED STATES PLASMA FRACTIONATION MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2024 (USD MILLION)
  • TABLE 300. UNITED STATES PLASMA FRACTIONATION MARKET SIZE, BY IMMUNOGLOBULINS, 2025-2032 (USD MILLION)
  • TABLE 301. UNITED STATES PLASMA FRACTIONATION MARKET SIZE, BY METHOD OF FRACTIONATION, 2018-2024 (USD MILLION)
  • TABLE 302. UNITED STATES PLASMA FRACTIONATION MARKET SIZE, BY METHOD OF FRACTIONATION, 2025-2032 (USD MILLION)
  • TABLE 303. UNITED STATES PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 304. UNITED STATES PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 305. UNITED STATES PLASMA FRACTIONATION MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 306. UNITED STATES PLASMA FRACTIONATION MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 307. CANADA PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 308. CANADA PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 309. CANADA PLASMA FRACTIONATION MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2024 (USD MILLION)
  • TABLE 310. CANADA PLASMA FRACTIONATION MARKET SIZE, BY IMMUNOGLOBULINS, 2025-2032 (USD MILLION)
  • TABLE 311. CANADA PLASMA FRACTIONATION MARKET SIZE, BY METHOD OF FRACTIONATION, 2018-2024 (USD MILLION)
  • TABLE 312. CANADA PLASMA FRACTIONATION MARKET SIZE, BY METHOD OF FRACTIONATION, 2025-2032 (USD MILLION)
  • TABLE 313. CANADA PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 314. CANADA PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 315. CANADA PLASMA FRACTIONATION MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 316. CANADA PLASMA FRACTIONATION MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 317. MEXICO PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 318. MEXICO PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 319. MEXICO PLASMA FRACTIONATION MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2024 (USD MILLION)
  • TABLE 320. MEXICO PLASMA FRACTIONATION MARKET SIZE, BY IMMUNOGLOBULINS, 2025-2032 (USD MILLION)
  • TABLE 321. MEXICO PLASMA FRACTIONATION MARKET SIZE, BY METHOD OF FRACTIONATION, 2018-2024 (USD MILLION)
  • TABLE 322. MEXICO PLASMA FRACTIONATION MARKET SIZE, BY METHOD OF FRACTIONATION, 2025-2032 (USD MILLION)
  • TABLE 323. MEXICO PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 324. MEXICO PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 325. MEXICO PLASMA FRACTIONATION MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 326. MEXICO PLASMA FRACTIONATION MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 327. BRAZIL